Amphastar Pharmaceuticals (AMPH) Competitors $30.81 +0.19 (+0.62%) Closing price 04:00 PM EasternExtended Trading$29.91 -0.90 (-2.93%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMPH vs. NUVL, MRUS, CRSP, TGTX, CYTK, AAPG, KRYS, ACAD, ADMA, and TLXShould you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry. Amphastar Pharmaceuticals vs. Its Competitors Nuvalent Merus CRISPR Therapeutics TG Therapeutics Cytokinetics Ascentage Pharma Group International Krystal Biotech ACADIA Pharmaceuticals ADMA Biologics Telix Pharmaceuticals Amphastar Pharmaceuticals (NASDAQ:AMPH) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Do analysts recommend AMPH or NUVL? Amphastar Pharmaceuticals currently has a consensus target price of $31.60, indicating a potential upside of 2.56%. Nuvalent has a consensus target price of $120.80, indicating a potential upside of 57.09%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts plainly believe Nuvalent is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Is AMPH or NUVL more profitable? Amphastar Pharmaceuticals has a net margin of 18.64% compared to Nuvalent's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 20.76% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals18.64% 20.76% 9.68% Nuvalent N/A -32.58%-30.14% Does the media favor AMPH or NUVL? In the previous week, Nuvalent had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 14 mentions for Nuvalent and 12 mentions for Amphastar Pharmaceuticals. Nuvalent's average media sentiment score of 1.52 beat Amphastar Pharmaceuticals' score of 1.34 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has better valuation & earnings, AMPH or NUVL? Amphastar Pharmaceuticals has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$731.97M1.96$159.52M$2.6711.54NuvalentN/AN/A-$260.76M-$4.90-15.69 Do insiders & institutionals believe in AMPH or NUVL? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 10.2% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, AMPH or NUVL? Amphastar Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. SummaryAmphastar Pharmaceuticals and Nuvalent tied by winning 8 of the 16 factors compared between the two stocks. Get Amphastar Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPH vs. The Competition Export to ExcelMetricAmphastar PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$4.26B$5.69B$9.68BDividend YieldN/A1.29%6.66%4.54%P/E Ratio11.5411.2482.6526.40Price / Sales1.9614.67529.10204.59Price / Cash6.127.4225.7028.92Price / Book2.023.2311.246.06Net Income$159.52M-$109.62M$3.28B$266.05M7 Day Performance1.55%0.16%0.15%-0.07%1 Month Performance45.26%20.27%8.36%5.83%1 Year Performance-36.79%28.75%54.25%17.89% Amphastar Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPHAmphastar Pharmaceuticals3.2803 of 5 stars$30.81+0.6%$31.60+2.6%-37.2%$1.43B$731.97M11.541,620Positive NewsNUVLNuvalent3.1103 of 5 stars$74.05-2.7%$118.91+60.6%-10.0%$5.49BN/A-15.1140News CoveragePositive NewsMRUSMerus2.6498 of 5 stars$65.74-2.6%$88.64+34.8%+29.1%$5.10B$36.13M-11.9537Positive NewsCRSPCRISPR Therapeutics3.3579 of 5 stars$54.13-0.3%$71.60+32.3%+8.6%$4.94B$37.31M-9.97460Positive NewsAnalyst RevisionTGTXTG Therapeutics4.552 of 5 stars$28.53-3.1%$46.25+62.1%+24.9%$4.67B$329M77.11290Positive NewsCYTKCytokinetics4.0652 of 5 stars$37.01-3.5%$71.58+93.4%-38.1%$4.59B$18.47M-7.26250News CoveragePositive NewsAnalyst ForecastOptions VolumeGap UpAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600High Trading VolumeKRYSKrystal Biotech4.7247 of 5 stars$146.77-2.5%$210.38+43.3%-24.3%$4.36B$290.52M29.83210Positive NewsACADACADIA Pharmaceuticals3.9994 of 5 stars$25.32-1.6%$28.88+14.0%+56.8%$4.34B$957.80M19.04510News CoverageAnalyst RevisionADMAADMA Biologics3.938 of 5 stars$17.01-4.4%$27.67+62.6%-0.3%$4.25B$426.45M19.78530Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/AAnalyst Revision Related Companies and Tools Related Companies NUVL Competitors MRUS Competitors CRSP Competitors TGTX Competitors CYTK Competitors AAPG Competitors KRYS Competitors ACAD Competitors ADMA Competitors TLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMPH) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMPH Stock Alerts